SIGA Technologies Inc. in New York, New York said today it received notice that the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), intends to award a contract for the company’s smallpox antiviral for the strategic national stockpile. SIGA says a protest from another company in the competition for the award first needs to be resolved before the award can take place.
Under the contract, BARDA calls for SIGA to deliver 1.7 million courses of its smallpox drug. The base contract, once awarded, is expected to generate revenues of about $500 million, with the entire contract, if all options are exercised, generating revenues of up to $2.8 billion.
While it appears to have helped having friends with friends in high places, in order for Stern to fully realize his value to SIGA, the company must first win the lawsuit that goes to trial on Monday over whether SIGA fully owns the rights to the vaccine (after a failed merger).